Summer UV + Melasma: Korea's May-September Management Plan

Why melasma gets worse in summer — and why the calendar matters more than any single treatment

Melasma is the chronic facial hyperpigmentation that appears as soft, symmetric brown patches across the cheeks, forehead, upper lip, and jawline. It is most common in women with skin phototypes III-V, often appears or worsens during pregnancy or hormonal change, and — the part this article exists to address — it almost always flares between May and September. That seasonal pattern is not coincidence. It is the central mechanism of the disease.

The trigger is ultraviolet radiation. UV-B (290-320 nm) and, to a meaningful extent, UV-A and visible light directly stimulate melanocytes through a cascade of intracellular signaling. A 2018 melanogenesis-inhibitor review in Acta Dermato-Venereologica walks through this cascade in detail: UV exposure upregulates α-MSH (alpha-melanocyte-stimulating hormone), activates the microphthalmia-associated transcription factor (MITF) pathway, and increases the activity of tyrosinase — the rate-limiting enzyme in melanin synthesis. The result is more pigment, deposited faster, in skin that is already predisposed by hormonal and vascular factors to over-pigment. In Seoul, the UV index typically climbs above 7 (very high) from late May, peaks at 9-10 in July and August, and only drops back below 6 in late September. Melasma follows that curve.

This is the part of melasma counseling that frustrates patients the most: the device or peel they came in for is the accelerator, not the foundation. The foundation is sun protection. Without aggressive daily UV defense from May through September, even the most evidence-backed laser, peel, or oral protocol will lose ground faster than it gains it. We say this in the first ten minutes of every consultation, and we will say it again at every point in this article, because it is the single most important sentence in melasma management.

Melasma is also chronically managed, not cured. There is no published modality — none — that produces permanent clearance in a single trip. What honest care can deliver is meaningful lightening, longer remission intervals, and a calibrated plan that respects the season the patient is in. The frame for this article is therefore: how does an international patient considering Seoul actually time their care around the May-September window?

Why Korean dermatology has built unusually deep melasma protocols

Korea is one of the highest-melasma-prevalence countries among Asian populations, with the bulk of cases concentrated in women in their 30s, 40s, and 50s — the same demographic that most often travels for aesthetic care. That clinical density has driven Korean dermatology to refine melasma protocols faster than markets where the condition is less prevalent. Two examples illustrate this.

First, the formal evidence base for oral tranexamic acid (TXA) in melasma was largely consolidated by Korean dermatology. A 2017 systematic review and meta-analysis in Acta Dermato-Venereologica by Kim and colleagues at Korea University College of Medicine pooled 11 studies (667 patients) and documented a mean MASI (Melasma Area and Severity Index) reduction of 1.60 points with TXA monotherapy and an additional 0.94-point reduction when TXA was added to standard topicals — with side effects limited to mild gastrointestinal discomfort, hypomenorrhea, and transient skin irritation. That paper effectively became the international reference for prescribing TXA in melasma. A 2024 meta-analysis in the Journal of Dermatological Treatment (22 studies, 1,280 patients) confirmed the result with the broader 2020s evidence base, identifying oral TXA as the most effective delivery route. A 2023 network meta-analysis in the Indian Journal of Dermatology, Venereology and Leprology further estimated the optimal dose at 250 mg three times daily for 12 weeks.

Second, low-fluence Q-switched Nd:YAG "laser toning" was popularized in Korea in the mid-2000s and is still most refined in Korean clinics — including a 2016 Korean cohort study in Annals of Dermatology (N=22 Korean women treated with photoacoustic twin-pulse mode 1,064 nm low-fluence Nd:YAG) that documented a 20.4% MASI reduction over five sessions at 2-week intervals with no notable adverse events. The technique is technically demanding precisely because it is performed at the edge of the pigment-disruption threshold — too aggressive and you induce post-inflammatory hyperpigmentation; too conservative and there is no benefit. Korean clinics carry a deep operator memory for this exact calibration.

None of this means "Korea is the best place." It means the published evidence base and the practical operator experience are unusually concentrated here for melasma specifically. That matters when you are choosing where to manage a chronic condition that responds to incremental, sub-threshold treatment more than to dramatic single-session intervention.

Four evidence-anchored modalities — and an honest depth rating for each

Melasma protocols are layered. No single agent below is a standalone solution, and the right combination depends on whether the patient's melasma is predominantly epidermal (responds better to topicals + toning), dermal (slower, less responsive), or mixed. Wood's-lamp and dermoscopy evaluation at consultation determines the layering.

1. Tranexamic acid — the most evidence-rich systemic agent (strong evidence)

Mechanism: TXA is a plasmin inhibitor originally developed for menorrhagia. In melasma it interrupts the UV-induced plasminogen-plasmin pathway that drives both melanocyte stimulation and vascular contribution. Oral TXA at 250 mg twice or three times daily over 8-12 weeks is the most-studied protocol; intralesional TXA microinjection is a second route used in some clinics.

Evidence depth: Strong. Three independent meta-analyses (Kim 2017, Wang 2023, Calacattawi 2024 — cited above) converge on a meaningful MASI reduction with acceptable safety in screened patients.
Honest limits: Not appropriate for patients with personal or family history of thromboembolic disease, current anticoagulant therapy, active malignancy, or recent surgery. Pre-prescription screening is mandatory. Effect typically reverses within months of discontinuation — TXA is a management tool, not a cure.
Where TXA fits in the Seoul plan: Often the foundation layer initiated 4-8 weeks before any device intervention, then continued through the summer window for patients screened as safe.

2. Hollywood Spectra (low-fluence Q-switched Nd:YAG toning) — Korean refinement (moderate evidence, technique-sensitive)

Mechanism: 1,064 nm Q-switched Nd:YAG delivered at sub-purpura fluences (typically 1.6-2.5 J/cm² with a 6-8 mm spot, multiple passes) selectively disrupts intracellular pigment without thermal damage to surrounding skin. Marketed as "laser toning" in Asia.

Evidence depth: Moderate. Kim 2016 (Korean cohort, PMID 27274626) documented ~20% MASI reduction across five biweekly sessions. A 2019 review in Journal of Cutaneous and Aesthetic Surgery on laser toning positions it as a third-line option for melasma refractory to topicals and peels.
Honest counter-evidence: Chan 2010 (Lasers in Surgery and Medicine) reported 14 cases of mottled facial depigmentation after laser toning — including five patients whose underlying melasma never improved before the depigmentation appeared. This complication is real and is the specific reason this technique should be performed only by operators with sustained low-fluence Nd:YAG experience.
Where toning fits in the Seoul plan: 4-6 sessions spaced 2-3 weeks apart. Particularly suited to international patients because each session has zero social downtime — you walk out and resume the day. Suspended during peak UV weeks (July-August) for patients who cannot maintain rigorous photoprotection.

3. Vbeam pulsed dye laser (PDL) for the vascular component — adjunct only (moderate evidence)

Mechanism: A subset of melasma — increasingly recognized in dermoscopy and histology — has a vascular contribution driven by elevated VEGF and increased dermal vasculature. 595 nm PDL selectively targets oxyhemoglobin and can reduce the vascular contribution that fuels pigment recurrence.

Evidence depth: Moderate, narrower than the toning evidence. Hassan 2018 split-face study in Journal of Dermatological Treatment compared PDL versus intense pulsed light on 28 patients and documented hemifacial mMASI reduction in both arms, with significant reduction in immunohistochemical VEGF staining — supporting the vascular-targeting hypothesis.
Honest limits: PDL is an adjunct, not a first-line monotherapy for melasma. It is most useful in the subset of patients with visible telangiectasias or post-inflammatory erythema layered with their pigment.
Where PDL fits in the Seoul plan: Added to the toning protocol for patients with documented vascular component on dermoscopic evaluation, typically 1-3 sessions interleaved with toning. See our Vbeam Seoul procedure page for protocol detail.

4. Chemical peels (glycolic, mandelic, PRX-T33) — surface accelerator (variable evidence)

Mechanism: Superficial chemical peels accelerate epidermal turnover and remove pigment-laden keratinocytes. Glycolic and mandelic acid peels have decades of published use; PRX-T33 (a TCA + hydrogen peroxide + kojic acid combination delivered without frosting) is a newer adjunct popular in Asia and Europe.

Evidence depth: Variable. Glycolic acid has the deepest published melasma evidence base. PRX-T33 evidence in melasma is currently case series and clinical-experience level, not large RCT — we frame it honestly as a complementary option rather than an evidence-equivalent of TXA or low-fluence Nd:YAG.
Honest limits: Skin phototypes IV-VI have a higher post-inflammatory hyperpigmentation risk with peels. Strict pre- and post-peel photoprotection is non-negotiable.
Where peels fit in the Seoul plan: Typically used as an adjunct between toning sessions to accelerate epidermal turnover. See our Chemical Peel Seoul procedure page.

For the full clinical map of how these modalities are sequenced in a single patient, see our Melasma Treatment Korea procedure page. The Hollywood Spectra Seoul page and Genesis Toning Seoul page detail the two laser-toning devices we use most often.

Timing your Seoul trip around peak UV — May/June arrival versus September/October arrival versus winter maintenance

The most useful planning question for an international patient is not "which laser" but "which month." UV exposure is the dominant variable in melasma response, and the calendar should drive the protocol — not the other way around.

May or June arrival (pre-peak). This is the strongest window for international patients who can commit to a 2-3 week initial visit. The reasoning: TXA can be started, baseline toning sessions 1-2 can be delivered, baseline dermoscopy can be documented, and the patient leaves Seoul with a prescribed home regimen (oral TXA continuation if appropriate, sunscreen protocol, prescription-strength topicals) that carries them through July and August. The patient returns in September or October for the second toning series when UV has dropped back to manageable levels.

September or October arrival (post-peak). This is the second-strongest window. By late September, summer UV damage is the freshest it will be all year, and the skin is in active recovery mode. Toning sessions performed in this window often produce visibly faster lightening because they are working with — not against — the seasonal recovery. The trade-off is that any TXA initiated now will be peaking after the worst UV month is already past, which is suboptimal for that single year but sets up the following May/June well.

Winter (November-March) — maintenance only. Winter visits are excellent for maintenance toning, peel series, and for procedures unrelated to melasma. They are not the ideal window to initiate first-line melasma treatment, because the visible response is harder to assess against the background of low UV exposure — you cannot easily tell whether improvement reflects the treatment or simply the seasonal lull.

July or August arrival (peak UV). We do not recommend initiating active toning or PDL series during peak UV unless the patient can guarantee aggressive daily photoprotection. Patients already on a maintenance plan can continue gentle TXA and topicals, but new device intervention during these weeks raises the post-inflammatory hyperpigmentation risk meaningfully. We are transparent about this rather than booking a peak-UV laser series simply because the slot is available.

What an honest May-September plan actually looks like

For an international patient flying into Seoul in late May or early June, a realistic and evidence-anchored plan looks roughly like this:

Pre-trip (4-8 weeks before arrival): Email consultation reviewing medical history, current melasma photos, current skincare, and prior treatment history. Screening for TXA contraindications. Confirmation that the patient understands melasma is chronically managed, not cured.
Day 1-2 in Seoul: In-person consultation with Wood's-lamp + dermoscopy evaluation, baseline standardized photography, MASI documentation, and protocol design. Sunscreen and home-regimen review.
Day 3-5: Toning session 1 (zero downtime). Initiation of oral TXA if appropriate.
Day 10-14: Toning session 2. Optional adjunct chemical peel or PDL session if dermoscopic findings support a vascular component.
Day 14+ (return home): Continue oral TXA. Strict daily SPF 50+ broad-spectrum sunscreen reapplied every 2 hours of sun exposure, hat + sunglasses + physical avoidance during 10 AM-4 PM peak. Prescription-strength topical regimen (typically a hydroquinone-based or non-hydroquinone alternative depending on patient preference and country regulation). Photo check-ins by email at 4 weeks and 8 weeks.
Return visit (September or October): Re-evaluation, toning sessions 3-4-5-6, dose-adjustment of TXA or transition to topical-only maintenance, finalization of long-term winter regimen.

This is a course, not an event. The patients who do best on this plan are the ones who understand from day one that the 4-6 toning sessions, the daily sun protection, the TXA course, and the prescription topical regimen are all parts of the same protocol — not alternatives to one another.

FAQ

Can I do the whole melasma protocol in one trip? Honest answer: no, not in any clinically meaningful way. Toning works best at 2-3 week intervals across 4-6 sessions (3-4 months elapsed). Oral TXA needs 8-12 weeks to express its effect. A single 2-week trip can deliver consultation, baseline session, and a prescription regimen — but it cannot deliver the full course. We will not pretend otherwise to make a single trip more appealing.

Is my melasma "curable"? No published protocol cures melasma. Honest goals are meaningful lightening, longer remission intervals, and reduced flare severity during high-UV months. We treat patients who have managed melasma successfully for 5-10 years with the right layered protocol, and we treat patients whose melasma has been refractory to multiple modalities. We will tell you, at consultation, which category your specific case is more likely to fall into.

What about oral glutathione or whitening IV drips? These are aggressively marketed in Asia, including Seoul. The published evidence for oral glutathione in melasma is limited and mixed; the evidence for IV glutathione in melasma is essentially absent. We do not recommend either as a first-line agent ahead of TXA, toning, peels, and topicals — which have meaningfully stronger published evidence.

Is tranexamic acid safe to take during summer? For patients screened as safe (no thromboembolic history, not on anticoagulants, not pregnant, no active malignancy), yes. We screen before prescribing and we recommend a pause if any new risk factor emerges during the course. Patients should disclose any new prescription medication or surgery during the TXA course.

Can I keep wearing my regular sunscreen? Maybe — most "regular" sunscreens are not strong enough for a melasma patient in summer Seoul or summer anywhere. The melasma standard is SPF 50+ broad-spectrum with iron oxides (to block visible light, which also stimulates melanocytes in skin phototypes IV-VI), reapplied every 2 hours of sun exposure. We typically demonstrate the application volume at consultation because patients consistently underapply.

What if I have darker skin (Fitzpatrick IV-VI)? Most of the published melasma evidence — including the studies above — is in Asian, Middle Eastern, and Latin populations with skin phototypes III-V. We have meaningful clinical experience with phototypes IV-VI, but we adjust fluences and peel concentrations more conservatively, and the risk of post-inflammatory hyperpigmentation is higher. We will tell you specifically what the calibration looks like at consultation.

What if my melasma is dermal rather than epidermal? Dermal melasma — where pigment is in the dermis rather than the epidermis — responds more slowly and less completely to most modalities. Wood's-lamp examination at consultation distinguishes the two patterns. We are honest with patients whose dermoscopic findings suggest a dermal-dominant pattern that the realistic ceiling on lightening is lower than for epidermal melasma — and we explain that protocol changes accordingly.

Reviewed by

This article was reviewed by Dr. SangYoul Yun, Board-Certified Dermatologist · AAD International Fellow (IFAAD) · ASLMS member · former Banobagi Dermatology Director. Last reviewed: 2026-05-17. Citations are anchored in PubMed and verified at publication. All evidence ratings reflect the strength of the published literature as of mid-2026 and may shift with future RCTs.

Sources

Kumari S, Tien Guan Thng S, Kumar Verma N, Gautam HK. Melanogenesis Inhibitors. Acta Dermato-Venereologica. 2018 Nov 5;98(10):924-931. PMID 29972222
Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. Acta Dermato-Venereologica. 2017 Jul;97(7):776-781. PMID 28374042
Wang WJ, Wu TY, Tu YK, Kuo KL, Tsai CY, Chie WC. The optimal dose of oral tranexamic acid in melasma: A network meta-analysis. Indian Journal of Dermatology, Venereology and Leprology. 2023;89(2):189-194. PMID 36332095
Calacattawi R, Alshahrani M, Aleid M et al. Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials. Journal of Dermatological Treatment. 2024;35(1):2361106. PMID 38843906
Kim JY, Choi M, Nam CH, Kim JS, Kim MH, Park BC, Hong SP. Treatment of Melasma with the Photoacoustic Twin Pulse Mode of Low-Fluence 1,064 nm Q-Switched Nd:YAG Laser. Annals of Dermatology. 2016 May 25;28(3):290-296. PMID 27274626
Shah SD, Aurangabadkar SJ. Laser Toning in Melasma. Journal of Cutaneous and Aesthetic Surgery. 2019;12(2):76-84. PMID 31413475
Chan NPY, Ho SGY, Shek SYN, Yeung CK, Chan HH. A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma. Lasers in Surgery and Medicine. 2010 Oct;42(8):712-9. PMID 20848553
Hassan AM, Elfar NN, Rizk OM, Eissa NY. Pulsed dye laser versus intense pulsed light in melasma: a split-face comparative study. Journal of Dermatological Treatment. 2018;29(7):725-732. PMID 29455565